| The increasing threat of Pseudomonas aeruginosa high-risk clones A Oliver, X Mulet, C López-Causapé, C Juan Drug Resistance Updates 21, 41-59, 2015 | 648 | 2015 |
| Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC G Cabot, S Bruchmann, X Mulet, L Zamorano, B Moyà, C Juan, ... Antimicrobial agents and chemotherapy 58 (6), 3091-3099, 2014 | 240 | 2014 |
| Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem E Riera, G Cabot, X Mulet, M García-Castillo, R del Campo, C Juan, ... Journal of antimicrobial chemotherapy 66 (9), 2022-2027, 2011 | 233 | 2011 |
| Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa PA Fraile-Ribot, G Cabot, X Mulet, L Periañez, ML Martín-Pena, C Juan, ... Journal of Antimicrobial Chemotherapy 73 (3), 658-663, 2018 | 179 | 2018 |
| Biological markers of Pseudomonas aeruginosa epidemic high-risk clones X Mulet, G Cabot, AA Ocampo-Sosa, MA Domínguez, L Zamorano, ... Antimicrobial agents and chemotherapy 57 (11), 5527-5535, 2013 | 144 | 2013 |
| Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants X Mulet, MD Maciá, A Mena, C Juan, JL Pérez, A Oliver Antimicrobial agents and chemotherapy 53 (4), 1552-1560, 2009 | 109 | 2009 |
| Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection C Lopez-Causape, E Rojo-Molinero, X Mulet, G Cabot, B Moya, ... PLoS One 8 (8), e71001, 2013 | 98 | 2013 |
| Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth X Mulet, B Moyá, C Juan, MD Macià, JL Pérez, J Blázquez, A Oliver Antimicrobial agents and chemotherapy 55 (10), 4560-4568, 2011 | 80 | 2011 |
| In Vivo Emergence of Resistance to Novel Cephalosporin–β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β … PA Fraile-Ribot, X Mulet, G Cabot, E del Barrio-Tofiño, C Juan, JL Pérez, ... Antimicrobial agents and chemotherapy 61 (9), 10.1128/aac. 01117-17, 2017 | 79 | 2017 |
| The Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to β-lactams, fitness, biofilm growth, and global regulation L Zamorano, B Moyà, C Juan, X Mulet, J Blázquez, A Oliver Antimicrobial agents and chemotherapy 58 (9), 5084-5095, 2014 | 75 | 2014 |
| Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals R Vatcheva-Dobrevska, X Mulet, I Ivanov, L Zamorano, E Dobreva, ... Microbial Drug Resistance 19 (5), 355-361, 2013 | 69 | 2013 |
| Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands M Díaz-Cañestro, L Periañez, X Mulet, ML Martin-Pena, PA Fraile-Ribot, ... European Journal of Clinical Microbiology & Infectious Diseases 37, 2191-2200, 2018 | 60 | 2018 |
| Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1 E Riera, MD Macià, A Mena, X Mulet, JL Pérez, Y Ge, A Oliver Journal of antimicrobial chemotherapy 65 (7), 1399-1404, 2010 | 53 | 2010 |
| Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: the SUPERIOR multicentre study S García-Fernández, M García-Castillo, G Bou, J Calvo, E Cercenado, ... International journal of antimicrobial agents 53 (5), 682-688, 2019 | 46 | 2019 |
| Interplay among resistance profiles, high-risk clones, and virulence in the Caenorhabditis elegans Pseudomonas aeruginosa infection model I Sánchez-Diener, L Zamorano, C López-Causapé, G Cabot, X Mulet, ... Antimicrobial Agents and Chemotherapy 61 (12), 10.1128/aac. 01586-17, 2017 | 46 | 2017 |
| Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains JJ Varga, M Barbier, X Mulet, P Bielecki, JA Bartell, JP Owings, ... BMC genomics 16, 1-27, 2015 | 45 | 2015 |
| Detection of the Novel Extended-Spectrum β-Lactamase OXA-161 from a Plasmid-Located Integron in Pseudomonas aeruginosa Clinical Isolates from Spain C Juan, X Mulet, L Zamorano, S Albertí, JL Pérez, A Oliver Antimicrobial agents and chemotherapy 53 (12), 5288-5290, 2009 | 42 | 2009 |
| Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing I Martínez-Ramos, X Mulet, B Moyá, M Barbier, A Oliver, S Albertí Antimicrobial agents and chemotherapy 58 (4), 2426-2429, 2014 | 37 | 2014 |
| In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain M Hernández-García, M García-Castillo, P Ruiz-Garbajosa, G Bou, ... Antimicrobial Agents and Chemotherapy 66 (3), e02161-21, 2022 | 35 | 2022 |
| Emergence of resistance to novel cephalosporin–β-Lactamase inhibitor combinations through the modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump MA Gomis-Font, C Pitart, E del Barrio-Tofiño, Y Zboromyrska, ... Antimicrobial Agents and Chemotherapy 65 (8), 10.1128/aac. 00089-21, 2021 | 32 | 2021 |
